Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma

NCT05600660 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: Orelabrutinib
DRUG: Rituximab
DRUG: Methotrexate

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University